BRIEF-Sobi and Biogen's Elocta approved in Europe for the treatment of haemophilia A By: Reuters: Company News November 24, 2015 at 02:06 AM EST * Says Sobi and Biogen's Elocta (rfviiifc) approved in Europe for the treatment of haemophilia a Read More >> Related Stocks: Biogen Idec